LVRNA009
Sponsors
AIM Vaccine Co., Ltd.
Conditions
SARS-CoV-2
Phase 3
Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad
NCT05428592
Start: 2023-04-30End: 2024-10-31Target: 1100Updated: 2023-02-02
A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19
NCT05682638
Start: 2023-01-30End: 2025-12-31Target: 34000Updated: 2023-02-21